(Q43244221)

English

Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial

scientific article published on 10 November 2009

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

object named as

Vesa Kataja

21

0 references

Akseli Hemminki

10

object named as

Akseli Hemminki

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Arja Jukkola-Vuorinen

4

object named as

Arja Jukkola-Vuorinen

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Pirkko-Liisa Kellokumpu-Lehtinen

2

object named as

Pirkko-Liisa Kellokumpu-Lehtinen

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

22

object named as

Petri Bono

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Riikka Huovinen

3

object named as

Riikka Huovinen

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

5

object named as

Minna Tanner

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

7

object named as

Riitta Kokko

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

8

object named as

Johan Ahlgren

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

9

object named as

Päivi Auvinen

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

12

object named as

Leena Helle

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Kenneth Villman

14

object named as

Kenneth Villman

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

20

object named as

Paul Nyandoto

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

15

object named as

Greger Nilsson

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

6

object named as

Raija Asola

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

11

object named as

Outi Paija

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

18

object named as

Marjo Pajunen

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Paula Poikonen-Saksela

19

object named as

Paula Poikonen

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

author name string

Lauri Nuortio

13

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Sirpa-Liisa Lahtela

16

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Kaisa Lehtiö

17

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Mika Leinonen

23

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Henrik Lindman

24

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

FinXX Study Investigators

25

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

10 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

1145-1151

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970307-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970307-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant docetaxel for node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970307-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970307-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970307-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970307-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970307-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970307-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970307-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970307-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Staging of breast cancer: new recommended standard procedure

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970307-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemotherapy in older women with early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970307-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970307-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970307-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970307-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel 100 versus 80 mg/m2 as adjuvant treatments of early breast cancer: an exploratory analysis of a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970307-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970307-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970307-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(09)70307-9

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43244221&oldid=2056365280"